-
公开(公告)号：US11427869B2
公开(公告)日：2022-08-30
申请号：US15687089
申请日：2017-08-25
申请人： THE BROAD INSTITUTE, INC. , MASSACHUSETTS INSTITUTE OF TECHNOLOGY , PRESIDENT AND FELLOWS OF HARVARD COLLEGE , THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： Aviv Regev , Vijay K. Kuchroo , Jellert Gaublomme , Youjin Lee , Chao Wang , Nir Yosef , Hongkun Park , James Kaminski
IPC分类号： C12Q1/6883 , C12Q1/6881 , G01N33/50
摘要： This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.
-
公开(公告)号：US11209440B2
公开(公告)日：2021-12-28
申请号：US15245748
申请日：2016-08-24
申请人： THE BROAD INSTITUTE, INC. , THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , PRESIDENT AND FELLOWS OF HARVARD COLLEGE , MASSACHUSETTS INSTITUTE OF TECHNOLOGY
发明人： Vijay Kuchroo , Aviv Regev , Jellert Gaublomme , Youjin Lee , Alexander K. Shalek , Chao Wang , Nir Yosef , Hongkun Park
摘要： This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.
-
公开(公告)号：US20200081017A1
公开(公告)日：2020-03-12
申请号：US16675398
申请日：2019-11-06
申请人： The Brigham and Women's Hospital, Inc. , The Broad Institute, Inc. , Massachusetts Institute of Technology , President and Fellows of Harvard College
发明人： Vijay K. Kuchroo , Aviv Regev , Jellert Gaublomme , Youjin Lee , Alexander K. Shalek , Chao Wang , Nir Yosef , Hongkun Park
IPC分类号： G01N33/68 , C12Q1/6883 , C07K16/28
摘要： This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.
-
公开(公告)号：US20170349950A1
公开(公告)日：2017-12-07
申请号：US15687089
申请日：2017-08-25
申请人： THE BROAD INSTITUTE INC. , MASSACHUSETTS INSTITUTE OF TECHNOLOGY , PRESIDENT AND FELLOWS OF HARVARD COLLEGE , THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： Aviv Regev , Vijay K. Kuchroo , Jellert Gaublomme , Youjin Lee , Chao Wang , Nir Yosef , Hongkun Park , James Kaminski
CPC分类号： C12Q1/6883 , C12Q1/6881 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , G01N33/5023
摘要： This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.
-
公开(公告)号：US20210317186A1
公开(公告)日：2021-10-14
申请号：US17226506
申请日：2021-04-09
申请人： The Brigham and Women's Hospital, Inc. , The Broad Institute, Inc. , Massachusetts Institute of Technology
发明人： Vijay K. Kuchroo , Chao Wang , Aviv Regev , Karthik Shekhar
IPC分类号： C07K14/705 , A61K38/20 , A61K38/17 , A61P37/00 , A61P1/00 , A61P35/00 , A61K39/395 , A61K45/06 , C07K14/54 , C07K16/24 , C07K16/28 , C12N15/113
摘要： Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.
-
公开(公告)号：US11884717B2
公开(公告)日：2024-01-30
申请号：US17226506
申请日：2021-04-09
申请人： The Brigham and Women's Hospital, Inc. , The Broad Institute, Inc. , Massachusetts Institute of Technology
发明人： Vijay K. Kuchroo , Chao Wang , Aviv Regev , Karthik Shekhar
IPC分类号： A61K38/20 , A61K38/17 , C07K14/705 , A61P37/00 , A61P1/00 , A61P35/00 , A61K39/395 , A61K45/06 , C07K14/54 , C07K16/24 , C07K16/28 , C12N15/113 , A61K39/00
CPC分类号： C07K14/70596 , A61K38/177 , A61K38/1709 , A61K38/208 , A61K39/3955 , A61K45/06 , A61P1/00 , A61P35/00 , A61P37/00 , C07K14/5434 , C07K16/244 , C07K16/2896 , C12N15/1136 , C12N15/1138 , A61K2039/575 , C12N2310/11 , C12N2310/14 , C12N2310/20 , A61K38/208 , A61K38/1709
摘要： Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.
-
公开(公告)号：US20220142948A1
公开(公告)日：2022-05-12
申请号：US17440282
申请日：2020-03-18
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , The Regents of the University of California
发明人： Aviv Regev , Chao Wang , Vijay K. Kuchroo , Nir Yosef , Allon Wagner , Johannes Fessler
IPC分类号： A61K31/132 , C12N5/0783 , C12N9/02 , C12N9/10 , C12N9/88 , C12N15/11
摘要： The subject matter disclosed herein is generally directed to modulation of Th17 differentiation and pathogenicity by use of metabolic targets. The metabolic targets are the molecules of the polyamine pathway or glycolysis pathway. Modulation of the polyamine pathway can shift Th17 pathogenicity and shift the transcriptome of Th17 cells to a Treg or Th1 transcriptome. The polyamine analogue DFMO can be used to modulate an inflammatory response. Inhibitors of enzymes in the glycolysis pathway can shift Th17 pathogenicity.
-
公开(公告)号：US11186825B2
公开(公告)日：2021-11-30
申请号：US15966244
申请日：2018-04-30
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
发明人： Aviv Regev , Ana Carrizosa Anderson , Le Cong , Vijay K. Kuchroo , Meromit Singer , Chao Wang
IPC分类号： C12N5/0783 , A61K35/17 , A61K39/00 , C12Q1/6881 , C12Q1/6886 , C07K14/00 , C07K14/47 , G01N33/50 , A61K45/06 , C12N15/10 , C12Q1/6883
摘要： The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
-
9.发明申请公开(公告)号：US20190100801A1
公开(公告)日：2019-04-04
申请号：US15966324
申请日：2018-04-30
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
发明人： Aviv Regev , Ana Carrizosa Anderson , Le Cong , Vijay K. Kuchroo , Meromit Singer , Chao Wang
IPC分类号： C12Q1/6881 , C12Q1/6853 , C12Q1/686 , C12Q1/6806
摘要： The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
-
公开(公告)号：US20190262399A1
公开(公告)日：2019-08-29
申请号：US16331410
申请日：2017-09-07
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
发明人： Chao Wang , Meromit Singer , Aviv Regev , Vijay K. Kuchroo
IPC分类号： A61K35/17 , G01N33/50 , A61P35/00 , G16H50/70 , G16H50/30 , G16B25/10 , C12Q1/6809 , C12Q1/6811 , C12Q1/6851 , C12Q1/6853
摘要： The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction or activation of immune cells. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from a modulated immune response.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.07 秒)
